Browse by author
Lookup NU author(s): Dr Nimantha De Alwis, Professor Chris Day
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Non-alcoholic fatty liver disease (NAFLD) is now the commonest liver disorder in the developed world affecting up to a third of individuals. It is closely associated with features of the metabolic syndrome, particularly obesity and diabetes. It can progress to cirrhosis, hepatocellular carcinoma and liver failure and is an increasing indication for transplantation. Dietary and genetic factors determine susceptibility to NAFLD and its progression. NAFLD may also be involved in the pathogenesis of cardiovascular disease. Most patients present with incidentally found abnormal liver blood tests. Diagnosis is usually one of exclusion. Liver biopsy is required for disease staging, but new imaging modalities and biomarkers are emerging which may eventually fulfil this role. There is, as yet no firm evidence-based treatment for NAFLD. Therapy is currently directed at treating components of the metabolic syndrome which may also be beneficial for the liver. The recent elucidation of the mechanisms leading to progressive disease suggests a variety of novel targets worthy of testing in animal models of NAFLD and subsequently in pilot studies in humans. © 2008 European Association for the Study of the Liver.
Author(s): de Alwis NMW, Day CP
Publication type: Review
Publication status: Published
Journal: Journal of Hepatology
Year: 2008
Volume: 48
Issue: S1
Pages: S104-S112
ISSN (print): 0168-8278
ISSN (electronic): 1600-0641
URL: http://dx.doi.org/10.1016/j.jhep.2008.01.009
DOI: 10.1016/j.jhep.2008.01.009
PubMed id: 18304679